Alzheimer's Association International Conference (AAIC)

The principal scientist of neuroscience discovery at Merck presented preclinical data at AAIC 2025 supporting the development of MK-2214, an anti-tau antibody designed to slow or prevent the progression of AD. [WATCH TIME: 5 minutes]

At AAIC 2025, Alberto Ramos, MD, FAAN, director of the Sleep Disorders program at the University of Miami, discussed the association between long sleep duration, specific sleep phenotypes, and progressive cognitive decline in Hispanic populations.

Researchers unveil promising findings from the GABriella trial, exploring a novel treatment for prodromal Alzheimer's disease at AAIC 2025.

The chief medical officer at Acumen Pharmaceuticals discussed the benefits of using the blood-based p-tau 217 biomarker to improve screening accuracy and reduce patient burden in AD. [WATCH TIME: 5 minutes]

The cofounder and chief science officer of the Alzheimer's Drug Discovery Foundation recapped some of the notable recent developments in the Alzheimer disease field presented at the 2025 Alzheimer’s Association International Conference.

Sam Gandy, MD, PhD, director of the Center for Cognitive Health at the Icahn School of Medicine at Mount Sinai, discussed his presentation on detecting toxic amyloid-β oligomers and their role in AD pathology at AAIC 2025.

Discover groundbreaking insights from the 2025 Alzheimer’s Association International Conference, featuring expert interviews on innovative treatments and diagnostics.

A recent meta-analysis reveals genistein's potential to enhance cognitive function in prodromal Alzheimer, urging further research for validation.

In the third episode, Salloway emphasizes the need for careful patient selection when prescribing donanemab to minimize serious risks, highlighting the value of the newly approved safer dosing regimen. Supported by Eli Lilly.

Dementia expert Stephen Salloway, MD, PhD, overviews the stepwise donanemab regimen approved by the FDA, citing how it not only reduces ARIA rates but preserves the same level of amyloid reduction as the original dosing. Supported by Eli Lilly.

New findings reveal ACP-204 shows no significant QT interval prolongation in healthy adults, supporting its safety for Alzheimer disease psychosis treatment.

Expert Stephen Salloway, MD, discussed findings from the TRAILBLAZER-ALZ 6 study, highlighting how a stepwise donanemab dosing regimen significantly lowered rates of ARIA in early Alzheimer disease. Supported by Eli Lilly.

Two experts from Cerevance discussed data from the company’s posters recently presented at AAIC 2025, which highlighted potential therapeutic targets for Alzheimer disease. [WATCH TIME: 5 minutes]

Yang Liu, PhD, co-founder, CEO, and chief scientific officer of OncoC4, provided commentary on the rationale and promising preclinical data behind ONC-841, a novel anti-SIGLEC10 antibody targeting amyloid and tau in Alzheimer disease.

At AAIC 2025, the head of AD, MS and Immunology Development Units at Biogen discussed ongoing research efforts targeting tau pathology in AD, specifically the company's investigational candidate BIIB080. [WATCH TIME: 6 minutes]

The chief scientific officer at Alzheon discussed the mechanism of valiltramiprosate and new data on toxic amyloid oligomers presented at the recently concluded Alzheimer’s Association International Conference.

New findings reveal the promising efficacy and safety of a subcutaneous lecanemab autoinjector for early Alzheimer disease treatment, enhancing patient care.

The professor of molecular neurology at the University of Cambridge highlighted recent research on tau protein aggregation in Alzheimer disease and other related tauopathies. [WATCH TIME: 6 minutes]

A real-world study reveals lecanemab's effectiveness in early Alzheimer's, showing stability or improvement in 83.6% of patients after two years.

Data presented at AAIC 2025 from a phase 2 study suggest that ABvac40 may slow cognitive decline in patients with Alzheimer disease, particularly among those who developed higher antibody levels.

UCB's bepranemab shows promise in slowing tau accumulation in early Alzheimer disease, marking an advancement in tau-targeted therapies.

The Emeritus Professor of Cognitive Neurology at VU University Medical Center talked about findings presented at AAIC 2025 from the phase 3 BROADWAY trial of obicetrapib in Alzheimer disease. [WATCH TIME: 3 minutes]

A groundbreaking phase 2 study evaluates PRI-002's potential to treat mild Alzheimer's symptoms, aiming for significant safety and efficacy insights by 2026.

Valiltramiprosate shows promising effects on brain structure and cognitive function in early Alzheimer disease, highlighting its potential for MCI treatment.

The chief development officer at Spinogenix shared initial results from the first cohort of the company’s phase 2 trial assessing SPG302 in Alzheimer disease presented at AAIC 2025. [WATCH TIME: 6 minutes]

New phase 2 data reveals AR1001's potential as a cognitive enhancer and disease-modifying therapy for mild to moderate Alzheimer's disease.

New data reveals lecanemab's long-term benefits for early Alzheimer's patients, showcasing improved cognitive outcomes and promising safety profiles over four years.

New findings reveal racial disparities in Alzheimer’s trial eligibility, highlighting higher screen failure rates among Black participants in the Auτonomy study.

The senior data scientist at Linus Health discussed how acoustic and speech-based metrics can be used to capture subtle cognitive signals during neuropsychological assessments. [WATCH TIME: 6 minutes]

AAV2-BDNF gene therapy shows promise in reversing cognitive decline in early Alzheimer's, enhancing neuronal function and safety in initial trials.